Homburger advises ADC Therapeutics in its follow-on public offering in the United States
ADC Therapeutics, a Swiss-based late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of antibody drug conjugates, announced the pricing of its upsized follow-on public offering of shares in the United States, thus raising gross proceeds of USD 204 m. In addition, certain existing shareholders had granted the underwriters an option to purchase additional sharesfor an aggregate amount of up to USD 30.6 m.
